

ART Regional Technical Consultation Objectives

1. Provide the latest evidence regarding ARV
2. supply for children, young adults and adults
3. Examine the implications of the new WHO 2009 recommendations, particularly regarding access, quality and sustainability
4. Discuss access barriers from the perspectives of the civil society, users, providers and administrators
5. Explore service integration models and check practical implementations
6. Discuss the regional framework for monitoring and assessment and the harmonization of indicators
7. Provide a framework to adapt and harmonize guides and supply chains in order to promote regional collaboration and improve cost effectiveness

1-2 Latest evidence regarding ART provision and the implications of the WHO guidelines

- Extend access and begin treatment earlier
- More secure regimens
- Cost (TDF- TDF/FTC-LOP/r- ATA/r, monitoring, genotype, rifabutin)
- Reviewing processes in GUA, HON, PAN, DOR, ELS, COR.
- Who evaluates compliance?


		Criteria	TDF	PI	VL CD4
ELS	2005	<350	NO	IDV	c/6
GUA	2009	350 **	Yes	LP/r	c/4-6
HON	2010	350 **	Yes	LP/r	c/6
NIC	2009	< 350	NO	LP/r	c/3
ELS	2005	<350	NO	NO	c/6
PAN	2007	<350	NO	NO	c3

New Challenges

- Program sustainability:
 - Management, Funding, Distribution, Updated Protocols, etc.
- Life expectancy versus reduction in mortality.
- Preventive approach in chronic complications: coronary disease, diabetes, dyslipidemias, renal function, etc.
- Development of new generations of care takers.
- Challenge of treating handicapped people
- If early detection is promoted, provide access to early treatment.

3. Discuss access barriers

- Poverty
- Weak health services
- Discrimination
- The providers' and users' attitude
- Sustainability
- Inadequate laboratory monitoring
- Excluded populations
- Lack of information



Information systems

- Examples of information records
- Quality improvement as an additional objective for the programs to guarantee efficiency and equity
- Improve information and publish it
- Explore opportunities for operational investigation when available information is not sufficient



Tratamiento ARV - MANGUA 1

Archivo Paciente Visita Laboratorio Enfermedades Tratamientos Observaciones Ayuda

Maria Aldana - NHC: 0235025

ARV actual

Fecha Inicio (**): 15/04/2009 ARV (**): Nevirapina (NVP) Tipo: NAN

Dosis (mg): [] Presentación: [] Vía administración: PO (vía oral)

Frecuencia: [] Proveedor: Fondo Mundial Genérico: []

Unid. entregadas: [] Unid. devueltas: [] Calc. Adherencia: [] Adherencia: []

Comprobar Esquema Finalizar TTM Efectos Sec. [] [] []

Aceptar Cancelar

ESQUEMA ACTUAL Ordenar esquemas por: Fecha Inicio

Fecha Inicio	ARV	TipoARV	Dosis	Presentación	Unid. Ent.	Adherencia	Ef. Sec.?
15/04/2009	Nevirapina (NVP)	NAN					No
15/04/2009	Zidovudina/Lamivudina (AZT+3TC)	2AN					No

ESQUEMAS ANTERIORES

Esq.	Fecha Inicio	Fecha Fin	Medicamentos	Motivo Cambio
------	--------------	-----------	--------------	---------------

Nuevo Tratamiento Cerrar

4. Integration

- Integration \neq comprehensive care
- Urgent need to define and strengthen activities by levels of care
- Indispensable integrated network approach
- Definition of packages by levels

“Situation in which the community, the sanitation personnel and the institutions within a care network have clearly defined, assume and solve the assigned tasks to respond to HIV at corresponding level, being capable of appropriately referring individuals for whom they are unable to provide care”.

5. Harmonization of M&E indicators

Monitoring and Assessment Plan



Benefits of the plan:

- Each indicator is well explained and defined
- There is a flowchart for collection and analysis
- There are processes that are already being implemented (Epired y CCLAB)



6. Procurement and Logistics

- Review concepts and opportunities for cost calculation and negotiation mechanisms
- Rethink calculations, negotiations and purchasing processes
- Redesign supply chains
- Project future needs according to the new scenarios
- Relate information with supplies

Prices PER MONTH (FE 2010)		US\$
1st line	AZT-3TC-NVP	12
1st line	TDF/FTC+EFV	19
2nd line	AZT-TDF-LOP/r	53
2nd line	AZT-TDF-ATA/R	410
3rd line	DRV-ETV-RAL	1600

NEXT STEPS

- We have identified specific situations that can be improved
- We have identified some ways to analyze them
- Analyze and propose specific solutions
- Follow-up (civil society, Gvmnt, Ag)
- Engage organizers to support these activities in the countries

Thank you!!!!!!

- Thank you to all of the participants!
- To the organizers, particularly Bisola, Rebecca, Victoria, Maria Jose, Ninnet and all the collaborators from AIDSTAR-one, PEPFAR, USAID, WHO
- To our families